Search Results

Q4 and full year 2022 in line with expectations at €2.7 million and €7.5 million, respectively U.S. level of sales stable in 2022 at...

Results were published in Respirology and provide further evidence supporting Cellvizio as a key complementary technology to robotic-assisted...

Improvement in gross margin driven by a more favorable sales mix and reduction in operating loss Solid business activity following strategic...

Tasly Mauna Kea Medical Engineering Technology Co. Ltd will expand reach of Cellvizio in China and launch a dedicated platform for neurosurgical...

Dynamic monitoring of the intestinal barrier with Confocal Laser Endomicroscopy demonstrated to be far superior to endoscopic and histologic...

Global 9-month sales slightly down (5%) at €4.8 million while sales in the United States grew 23% Mauna Kea Technologies today announced...

Mauna Kea Technologies today announces the appointment of Sacha Loiseau, Founder and current Chairman of the Board of Mauna Kea Technologies, to...

Mauna Kea Technologies postpones release of its 2022 Half-Year Results, which was originally planned for September 22, 2022, to not later than...

Results of the 20-patient study published in the European Journal of Nuclear Medicine and Molecular Imaging demonstrated the potential for high...

Stable YTD Revenue while Strategic Realignment Implemented 35% 1H U.S. Sales Growth offset by Declines in Asia Recently announced Tasly...

Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market. JV also to acquire...